Fair Value of MRNA stock based on Discounted Cash Flow (DCF)
MRNA ($434.46) is undervalued by 2.91% relative to our estimate of its Fair Value price of $447.46 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
MRNA ($434.46) is trading below its intrinsic value of $843.87, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
MRNA price to earnings (PE)
For valuing profitable companies with steady earnings
MRNA is good value based on its earnings relative to its share price (50x), compared to the US market average -8.74x)
MRNA is good value based on its earnings relative to its share price (50x), compared to the US Biotechnology industry average (280.41x)
MRNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
MRNA is poor value based on its book value relative to its share price (26.16x), compared to the US Biotechnology industry average (6.98x)
MRNA price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRNA is poor value relative to its rate of earnings growth, measured by PEG ratio (1.95x)
MRNA's financial health
MRNA's Earnings (EBIT) of $3.82B can safely cover interest payments on company debt ($433.00M)
MRNA's profit margin has increased (+509.3%) in the last year from (-459.5%) to (49.8%)
Assets to liabilities
Debt to equity
MRNA's short-term assets ($10.97B) exceed its short-term liabilities ($8.84B)
MRNA's short-term assets ($10.97B) exceed its long-term liabilities ($609.00M)
MRNA's debt to equity ratio (1.41) is considered high
MRNA's operating cash flow ($9.19B) is sufficient to service the company's debt ($433.00M)
Moderna Stock FAQ
What is Moderna's quote symbol?
(NASDAQ: MRNA) Moderna trades on the NASDAQ under the ticker symbol MRNA. Moderna stock quotes can also be displayed as NASDAQ: MRNA.
What is the 52 week high and low for Moderna (NASDAQ: MRNA)?
(NASDAQ: MRNA) Moderna's 52-week high was $497.49, and its 52-week low was $63.64. It is currently -12.67% from its 52-week high and 582.68% from its 52-week low.
How much is Moderna stock worth today?
(NASDAQ: MRNA) Moderna currently has 403,646,312 outstanding shares. With Moderna stock trading at $434.46 per share, the total value of Moderna stock (market capitalization) is $175.37B.
Moderna stock was originally listed at a price of $18.60 in Dec 7, 2018. If you had invested in Moderna stock at $18.60, your return over the last 2 years would have been 2,235.81%, for an annualized return of 383.3%.
How much is Moderna's stock price per share?
(NASDAQ: MRNA) Moderna stock price per share is $434.46 today (as of Sep 15, 2021).
What is Moderna's Market Cap?
(NASDAQ: MRNA) Moderna's market cap is $175.37B, as of Sep 16, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Moderna's market cap is calculated by multiplying MRNA's current stock price of $434.46 by MRNA's total outstanding shares of 403,646,312.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.